Brief: Galera Announces FDA Orphan Drug Designation Granted To Rucosopasem For Pancreatic Cancer
18/05/2023 13:10
Galera Therapeutics Inc GRTX.O :
* GALERA ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO
RUCOSOPASEM FOR PANCREATIC CANCER
* GALERA ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO
RUCOSOPASEM FOR PANCREATIC CANCER
* GALERA THERAPEUTICS- BELIEVE RUCOSOPASEM HAS POTENTIAL TO
IMPROVE EFFICACY OF SBRT FOR PANCREATIC CANCER, SEES TOPLINE
DATA FROM GRECO-2 BY END OF NEXT YEAR
Source text for Eikon: ID:nGNXDwt9x
Further company coverage: GRTX.O
Recent news on Galera Therapeutics
See all newsBrief: Galera Therapeutics Says Nasdaq Will Delist Co's Common Stock By Filing Form 25 With SEC On Sept 4
Brief: Galera Announces Board Approval Of Complete Liquidation And Dissolution
Brief: Galera Therapeutics Receives Written Notice From Nasdaq Indicating That Nasdaq Hearings Panel Determined To Delist Co’s Shares
Brief: Alpha Pharma Investments Llc Reports 10.899% Passive Stake In Galera Therapeutics
Brief: Galera Adopts Limited Duration Stockholder Rights Agreement